EP Patent

EP1704152A2 — Crystalline clopidogrel hydrobromide and processes for preparation thereof

Assigned to Teva Pharmaceutical Industries Ltd · Expires 2006-09-27 · 20y expired

What this patent protects

Provided are crystalline forms of clopidogrel hydrobromide and processes for their preparation.

USPTO Abstract

Provided are crystalline forms of clopidogrel hydrobromide and processes for their preparation.

Drugs covered by this patent

Patent Metadata

Patent number
EP1704152A2
Jurisdiction
EP
Classification
—
Expires
2006-09-27
Drug substance claim
No
Drug product claim
No
Assignee
Teva Pharmaceutical Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.